Trial of Psilocybin versus Escitalopram for Depression
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Psilocybin may have antidepressant properties, but direct comparisons between psilocybin and established treatments for depression are lacking. METHODS: In a phase 2, double-blind, randomized, controlled trial involving patients with long-standing, moderate-to-severe major depressive disorder, we compared psilocybin with escitalopram, a selective serotonin-reuptake inhibitor, over a 6-week period. Patients were assigned in a 1:1 ratio to receive two separate doses of 25 mg of psilocybin 3 weeks apart plus 6 weeks of daily placebo (psilocybin group) or two separate doses of 1 mg of psilocybin 3 weeks apart plus 6 weeks of daily oral escitalopram (escitalopram group); all the patients received psychological support. The primary outcome was the change from baseline in the score on the 16-item Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR-16; scores range from 0 to 27, with higher scores indicating greater depression) at week 6. There were 16 secondary outcomes, including QIDS-SR-16 response (defined as a reduction in score of >50%) and QIDS-SR-16 remission (defined as a score of ≤5) at week 6. RESULTS: A total of 59 patients were enrolled; 30 were assigned to the psilocybin group and 29 to the escitalopram group. The mean scores on the QIDS-SR-16 at baseline were 14.5 in the psilocybin group and 16.4 in the escitalopram group. The mean (±SE) changes in the scores from baseline to week 6 were -8.0±1.0 points in the psilocybin group and -6.0±1.0 in the escitalopram group, for a between-group difference of 2.0 points (95% confidence interval [CI], -5.0 to 0.9) (P = 0.17). A QIDS-SR-16 response occurred in 70% of the patients in the psilocybin group and in 48% of those in the escitalopram group, for a between-group difference of 22 percentage points (95% CI, -3 to 48); QIDS-SR-16 remission occurred in 57% and 28%, respectively, for a between-group difference of 28 percentage points (95% CI, 2 to 54). Other secondary outcomes generally favored psilocybin over escitalopram, but the analyses were not corrected for multiple comparisons. The incidence of adverse events was similar in the trial groups. CONCLUSIONS: On the basis of the change in depression scores on the QIDS-SR-16 at week 6, this trial did not show a significant difference in antidepressant effects between psilocybin and escitalopram in a selected group of patients. Secondary outcomes generally favored psilocybin over escitalopram, but the analyses of these outcomes lacked correction for multiple comparisons. Larger and longer trials are required to compare psilocybin with established antidepressants. (Funded by the Alexander Mosley Charitable Trust and Imperial College London's Centre for Psychedelic Research; ClinicalTrials.gov number, NCT03429075.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In two recent psilocybin clinical trials, ~95% of all volunteers were eliminated on the basis of exclusion criteria”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [8]
In the citing paper
“Amelioration of symptomatic depression in pilot studies of major depressive disorder, including those that compared psilocybin with escitalopram 8,9 and that investigated its use in treatment-resistant depression, 10 has suggested therapeutic potential for this agent.”
From Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression (2022) · cites this paper as [9]
In the citing paper
“Studies have used inactive placebos (e.g., [17, 35]), active placebos whose effects considerably differ from the acute effects of serotonergic psychedelics (e.g., [15, 36, 37]), or doses of psilocybin presumably too low to maintain blinding (e.g., [38, 39])”
In the citing paper
“Contemporary clinical studies have involved one to three dosing sessions (e.g., [38, 39, 117])”
In the citing paper
“Research on MDD, anxiety and depressive symptoms associated with life-threatening cancer, and TRD showed the most robust evidence, supported by a non-randomized study 72 and several RCTs. 26,31-33,60,73-77”
From The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges (2024) · cites this paper as [26]
15 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Malhi, G. S., & Mann, J. J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31948-2 · Cited by 4,099
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540
Self-citationEffects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
Cited by
Items 701–800 of 1,001
Self-administration of Psilocybin in the Setting of Treatment-resistant Depression.
Lyons, A. (2022) · PubMed Central · Cited by 8
Legalization of Psychedelic Substances
Downey, L. A., Sarris, J. J., & Perkins, D. (2021) · JAMA · doi:10.1001/jama.2021.19372 · Cited by 8
Psilocybin Combines Rapid Synaptogenic And Anti-Inflammatory Effects In VitroPreprint
Smedfors, G., Glotfelty, E. J., Kalani, N., Hjelle, C. P., Horntvedt, O., Wellfelt, K., Brodin, A., von Kieseritzky, F., Olson, L., & Karlsson, T. E. (2022) · Research Square · doi:10.21203/rs.3.rs-1321542/v1 · Cited by 8
Kim, V., Wilson, S. M., & Woesner, M. E. (2024) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001941 · Cited by 11
Roméo, B., Kervadec, E., Fauvel, B., Strika-Bruneau, L., Amirouche, A., Verroust, V., Piolino, P., & Benyamina, A. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111300 · Cited by 10
Villiger, D. (2025) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2025.06.003 · Cited by 7
Joga, R., Yerram, S., Patnam, J. D., Choudhary, K. K., Varpe, P. C., Raghuvanshi, R. S., & Srivastava, S. (2025) · Health Policy · doi:10.1016/j.healthpol.2025.105392 · Cited by 7
Thuery, G., Sheridan, C., Iusan, P., Brar, G., Ledden, K., Freyne, A., Kelly, J. R., & Harkin, A. (2025) · Acta Neuropsychiatrica · doi:10.1017/neu.2025.10030 · Cited by 8
Genetics and Neurobiology of Treatment-Resistant Depression—A Review
Płaza, O., Gałecki, P., Bliźniewska-Kowalska, K. M., Gałecka, M., Brońska, A., Jornet-Plaza, J., Szurek, A., & Szulc, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262211016 · Cited by 8
“Psychedelic-assisted therapies, including psilocybin, may act through 5-HT2A receptor-mediated neuroplastic mechanisms that facilitate cognitive and emotional flexibility, also offering promise for TRD [98,99].”
Psilocybin in late-life mental health: Addressing depression, loneliness, and existential anxiety
Konstantinou, G., Rosenblat, J. D., Hales, S., Husain, M. I., & Blumberger, D. M. (2025) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2025.12.005 · Cited by 7
Maltby, C. J., Klein, A. K., Paschen, E., Pinto, J., Dvořák, D., Hedde, J. R., Hanks, A. N., Bianchi, M., & Hughes, Z. A. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811251395386 · Cited by 11
“Major randomized controlled trials of psilocybin for treat-ment-resistant or MDD (Goodwin et al., 2022; Davis et al., 2020; Carhart-Harris et al., 2021; Raison et al., 2023) and subsequent meta-analyses (Swieczkowski et al., 2025) report robust antidepressant efficacy without evidence of…”
Taylor, J. J., Szigeti, B., Silverberg, N. D., Ahmadzad-Asl, M., Kare, M. R., Webler, R. D., Orsini, D. K., Rosenblat, J. D., Bschor, T., Baethge, C., et al. (2026) · The Lancet Psychiatry · doi:10.1016/s2215-0366(26)00018-0 · Cited by 7
Psychedelika in der Psychiatrie – Entwicklungen und die Stellung in Deutschland
Herwig, U., Mertens, L. J., Rosal, S. P., Koller, G., Jungaberle, A., Borgwardt, S., & Gründer, G. (2023) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-1981-3152 · Cited by 7
“In England erfolgt bereits wieder seit einem Jahrzehnt insbeson-dere am Imperial College in London Psychedelikaforschung mit in den letzten Jahren mehreren publizierten klinischen Studien zu Psi-locybin bei depressionen (u. a. [52, 53]).”
BackgroundIs psilocybin an effective antidepressant and what is its Mechanism of action?
Mann, J. J. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100906 · Cited by 8
“The first major study came from Carhart-Harris et al.2 and used a complex dosing plan that involved either two 25mg doses of psilocybin given 3 weeks apart, overlapping with 6 weeks of placebo, or two 1 mg doses of psilocybin 3 weeks apart, overlapping with 6 weeks of a selective serotonin reuptake inhibitor (SSRI) an…”
MethodInfluentialPsychedelics, With a Focus on Psilocybin: Issues for the Clinician
Garakani, A., Alexander, J. L., Sumner, C. R., Pine, J. H., Gross, L. S., Raison, C. L., Aaronson, S. T., & Baron, D. A. (2023) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000729 · Cited by 7
Armand, S., Larsen, K., Madsen, M. K., Ozenne, B., Preller, K. H., Knudsen, G. M., Stenbæk, D. S., & Fisher, P. M. (2023) · Neuroscience Applied · doi:10.1016/j.nsa.2023.103934 · Cited by 7
Muir, O. S., Shinozuka, K., Beutler, B. D., Arenas, A., Cherian, K. N., Evans, V. D., Fasano, C., & Tabaac, B. J. (2024) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001720 · Cited by 7
Hervig, M. E.-S., Zühlsdorff, K., Olesen, S. F., Phillips, B. U., Božič, T., Dalley, J. W., Cardinal, R. N., Alsiö, J., & Robbins, T. W. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06586-w · Cited by 7
“…understanding of mechanisms under - lying cognitive flexibility and RL. Psilocybin and other psychedelics are receiving increased attention for their therapeutic potential in treating neuropsy - chiatric disorders such as MDD and anxiety (Carhart-Harris et al. 2016, 2021 ; Goldberg et al. 2020 ).”
BackgroundBerlowitz, I., Torres, E. G., Ruiz-Macedo, J. C., Wolf, U., Maake, C., & Martin-Soelch, C. (2024) · Health Education & Behavior · doi:10.1177/10901981231213348 · Cited by 1
“…as potential therapeutics (e.g., for depression or PTSD), some of which now labeled “breakthrough therapies” by the FDA (Butler et al., 2020; Carhart-Harris et al., 2021; Chi & Gold, 2020; dos Santos & Hallak, 2021; Fisher et al., 2021; Kyzar et al., 2017; Luoma et al., 2020; Nichols,…”
A narrative exploration of psilocybin’s potential in mental health
Min, H., Park, S.-Y., Park, J., Na, S., Lee, H.-S., Kim, T., Ham, J., & Park, Y.-T. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1429373 · Cited by 7
Amid magic and menace: psychiatrists’ attitudes to psilocybin therapy
Gribben, A. D., Burke, T., Harrington, C., Husein, A., Murnane, K. S., Hendricks, P. S., Tobin, K., Ivers, J., Thuery, G., Harkin, A., et al. (2024) · Irish Journal of Psychological Medicine · doi:10.1017/ipm.2024.49 · Cited by 7
“…clinical trial data, of increasing quality, suggests that psilocybin therapy may play a meaningful therapeutic role in major depressive disorder (Carhart-Harris et al., 2021; Davis et al., 2021; Raison et al., 2023; von Rotz et al., 2023), treatment-resistant depression (TRD) (Carhart-Harris et…”
Psilocybin as a disease-modifying drug—a salutogenic approach in psychiatry
Spangemacher, M., Mertens, L. J., Färber, L. V., Jungaberle, A., Jungaberle, H., & Gründer, G. (2024) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2024.0224 · Cited by 12
Treatment Expectancies and Psilocybin vs Escitalopram for Depression
Dutcher, E. G., & Krystal, A. D. (2024) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2024.4387 · Cited by 8
Wahba, M., Hayes, C., Kletter, M., & McAllister-Williams, H. (2024) · BJPsych Open · doi:10.1192/bjo.2024.768 · Cited by 7
Irrmischer, M., Puxty, D. J., Yıldırım, B. O., Deijen, J. B., & Engelbregt, H. (2025) · Psychopharmacology · doi:10.1007/s00213-024-06733-3 · Cited by 9
“More recently, a trial comparing psilocybin with escitalopram, a SSRI antidepressant, in patients with long-standing, mild-to-severe depression demonstrated a similar reduction in depressive complaints compared to baseline at a 6-week follow-up (Carhart-Harris et al. 2021).”
Fischman, L. G. (2025) · Frontiers in Psychology · doi:10.3389/fpsyg.2025.1469559 · Cited by 8
Psychedelics and Suicide-Related Outcomes: A Systematic Review
Meshkat, S., Malik, T., Zeifman, R. J., Swainson, J., Zhang, Y., Burback, L., Winkler, O., Greenshaw, A. J., Reichelt, A. C., Vermetten, E. H. G. J. M., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14051416 · Cited by 9
Silva, F., Butlen‐Ducuing, F., Guizzaro, L., & Balabanov, P. (2025) · Neuroscience Applied · doi:10.1016/j.nsa.2025.105516 · Cited by 7
“…of psychedelics has received a surge of interest in recent years, marked by a proliferation in academic research, development initiatives and clinical trials investigating the therapeutic potential of these substances in a range of conditions (Nutt & Carhart-Harris, 2021; Phelps et al., 2022).”
Dourron, H. M., Bradley, M., Simonsson, O., Copes, H., Grossman, D., Shallcross, R. A., & Hendricks, P. S. (2025) · Psychedelic Medicine · doi:10.1089/psymed.2024.0036 · Cited by 7
Coleman, C. R., Shinozuka, K., Tromm, R., Dipasquale, O., Kaelen, M., Roseman, L., Muthukumaraswamy, S. D., Nutt, D. J., Barnett, L., & Carhart-Harris, R. L. (2025) · Human Brain Mapping · doi:10.1002/hbm.70209 · Cited by 7
Self-citationWhat fMRI studies say about the nature of the psychedelic effect: a scoping review
Beneš, M., Páleníček, T., & Horáček, J. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1606798 · Cited by 9
Millón, M. B. B., Noguera, L., Bruno, D., Vita, L., Zanino, M., Kassuha, D., Ortiz, J. E., Feresin, G. E., Díaz-Dellavalle, P., Orosco, L. L., et al. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02167-3 · Cited by 7
“While growing evidence supports the ef fi cacy of psychedelics such as psilocybin, ayahuasca, and LSD for treating psychiatric disorders [4, 17 – 24], clinical evidence for 5-MeO-DMT is limited to a few clinical trials [6 – 8, 13], anecdotal To our knowledge, this is the fi rst clinical trial to…”
Psychedelic research and the real world
Appelbaum, P. S. (2022) · Nature · doi:10.1038/d41586-022-02875-6 · Cited by 7
Malpractice and Other Civil Liability in Psychedelic Psychiatry
Holoyda, B. J. (2023) · Psychiatric Services · doi:10.1176/appi.ps.20220528 · Cited by 7
Escamilla-Orozco, R. I., González-Trujano, M. E., Mariscal, J. M. G., Torres-Valencia, J. M., Guzmán-González, H., Vega, J. L., & Loizaga-Velder, A. K. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2246459 · Cited by 8
“A recent trial comparing outcomes of psilocybin-assisted treatment with escitalopram found no significant differences (Barba et al. 2022; Carhart-Harris et al. 2021).”
BackgroundMethodResultConvulsive therapy for psychiatric disorders
Kaster, T. S., & Blumberger, D. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18496-3.00010-0 · Cited by 7
Poulin, J. M., Bigford, G. E., Lanctôt, K. L., Giacobbe, P., Schaffer, A., Sinyor, M., Rabin, J. S., Masellis, M., Singnurkar, A., Pople, C. B., et al. (2024) · Trials · doi:10.1186/s13063-024-08268-6 · Cited by 7
“…psilocybin dose for this study is reported to be unaffected by age and body mass with respect to total drug exposure and maximum plasma concentration [80] and was comparable to the selective serotonin reuptake inhibitor (SSRI) escitalopram in terms of both efficacy and adverse event frequency [22].”
MethodWang, Y., Zhang, C., Li, M., & Wang, X. (2024) · Fundamental Research · doi:10.1016/j.fmre.2024.09.006 · Cited by 8
“Recent studies highlight the potential of psychedelics in treating neuropsychiatric disorders, including depression, anxiety, and post-traumatic stress disorder [ 6 , 7 ].”
Rab, S. F., Raison, C. L., & Marseille, E. A. (2024) · Psychedelics. · doi:10.61373/pp024r.0025 · Cited by 7
“Recent clinical trials have evaluated psilocybin’s effectiveness as both monotherapy for depression (3, 4), and as an adjunct to established antidepressantregimens(2,23).”
BackgroundZhai, H., Wang, Y., & Wang, X. (2024) · Neuroscience Bulletin · doi:10.1007/s12264-024-01341-9 · Cited by 7
Psychedelics and Hallucinogens in Psychiatry: Finding New Pharmacological Targets
de Sousa, T. R., Rema, J., Machado, S. E. D. C., & Novais, F. (2021) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026621666211201145800 · Cited by 8
Malaca, S., Bottinelli, C., Fanton, L., Cartiser, N., Carlier, J., & Busardò, F. P. (2023) · Metabolites · doi:10.3390/metabo13010092 · Cited by 7
Rethinking the medication management of major depression
Mann, J. J., & Rizk, M. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2190886 · Cited by 10
“Dose escalation after initial non-response is beneficial with some drugs like venlafaxine, but rarely works for SSRIs [188].”
BackgroundInfluentialCardiac Arrest Associated With Psilocybin Use and Hereditary Hemochromatosis
Bae, S., Vaysblat, M., Bae, E. J., Dejanovic, I., & Pierce, M. (2023) · Cureus · doi:10.7759/cureus.38669 · Cited by 9
“A recent randomized control trial compared escitalopram to psilocybin, showing similar efficacy for depression, with psilocybin having a milder side effect profile [8].”
BackgroundDearnley, B., Dervinis, M., Shaw, M., & Okun, M. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.22.457198 · Cited by 9
“…states of wakefulness and consciousness (Vollenweider and Geyer, 2001; Foster et al., 2016; Brecier et al., 2021) and by the therapeutic potential of this class of compounds (Carhart-Harris et al., 2016b, 2017; Johnson and Griffiths, 2017; Roseman et al., 2018; Carhart-Harris et al., 2021).”
BackgroundMeditative in-action: an endogenous epistemic venturePreprint
Pagnoni, G., & Guareschi, F. T. (2021) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/mdbgq · Cited by 10
Penn, A., & Yehuda, R. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2023.0017 · Cited by 8
“63 Subsequently, the research team published a critique of the QIDS as a measure of depression despite having selected it as their primary outcome.”
Targeting the 5-HT2A Receptor for Developing Psychedelic Drugs and Beyond
Ali, S., Tian, X., Cunningham, K. A., & Zhou, J. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01156 · Cited by 9
Innovations in group-based psilocybin-assisted therapy of major depression in patients with cancer
Thrul, J., Kozak, Z., Carducci, M. A., Garcia‐Romeu, A., & Yaden, D. B. (2024) · Cancer · doi:10.1002/cncr.35127 · Cited by 6
“7 Both of these studies show that the costs of psychedelic ‐ assisted therapy are primarily driven by the psycho-therapy component.”
BackgroundJiwani, Z., Goldberg, S. B., Stroud, J., Young, J., Curtin, J., Dunne, J. D., Simonsson, O., Webb, C. A., Carhart-Harris, R., & Schlosser, M. (2025) · PLOS ONE · doi:10.1371/journal.pone.0310160 · Cited by 6
Self-citationExperiments in medicalization: psychedelic therapy in Switzerland and Australia
Langlitz, N. (2025) · BioSocieties · doi:10.1057/s41292-025-00369-y · Cited by 6
Psychedelics for major depression—From controlled research settings into broader clinical use
Avram, M., & Borgwardt, S. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102361 · Cited by 8
Rucker, J., Mantingh, T., Kerr‐Gaffney, J., Bird, C., Chu, P., Modlin, N. L., Campbell‐Coker, K., Hambleton, S., Seath, P., Hignett, R., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04541-0 · Cited by 6
Self-administration of Psilocybin for the Acute Treatment of Migraine: A Case Report.
Lawrence, D. W. (2023) · PubMed Central · Cited by 6
Navigating the “Psychedelic Renaissance”: From Research to Reality
Payer, D. E., Klaire, S. S., Morisano, D., Bartram, M. H., Williams, M. T., & Rush, B. R. (2024) · International Journal of Mental Health and Addiction · doi:10.1007/s11469-024-01288-y · Cited by 6
“Building on a significant body of evidence showing the effectiveness of psilocybin-assisted therapy in treating depression (Carhart-Harris et al., 2021), Weiss et al. (2024) add nuance to the mechanisms underlying treatment success, showing a causal role for acute psychological experiences such as…”
Scuro, J. (2024) · Social Compass · doi:10.1177/00377686241301923 · Cited by 6
“MDMA is the furthest along, in phase III trials for post-traumatic stress disorder (PTSD), while psilocybin is in phase II trials for treatment-resistant depression (Carhart-Harris et al., 2021; Mitchell et al., 2021).”
Ellis, S., Bostian, C. M., Donnelly, A. J., Feng, W., Eisen, K., Lean, M., Conlan, E., Ostacher, M. J., Aaronson, S. T., & Suppes, T. M. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.119655 · Cited by 11
Bălăeţ, M., Trender, W. R., Lerede, A., Hellyer, P. J., & Hampshire, A. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251346729 · Cited by 6
“This interest is driven by the therapeutic potential of psychedelics like psilocybin for severe depression (Carhart-Harris et al., 2021), as well as research suggesting mood-enhancing effects in ‘naturalistic settings’, that is, as they are commonly used in the real world (Forstmann et al., 2020).”
Galdino, T. P., de Oliveira, L. C., da Luz, M. A., Barbosa, R. C., Torres, M. D. C. D. M., Sivieri, K., Fernandes, P. A., dos Santos, M. L., de Lima, A. G. B., Silva, S. M. D. L., et al. (2025) · ACS Omega · doi:10.1021/acsomega.5c02751 · Cited by 7
Examining the potential of psilocybin and 5-MeO-DMT as therapeutics for traumatic brain injury
Plummer, Z., Allen, J., Brand, J., Mayo, L. M., Shultz, S. R., & Christie, B. R. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111448 · Cited by 6
5-HT2A receptors shape whole-brain monoaminergic coherence in male mice
Butler, J. J., Virgili, M., Giovanni, G. D., Chagraoui, A., Beyeler, A., & Deurwaerdère, P. D. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111437 · Cited by 7
Toward Standardized Products Containing Biomass of Psilocybe Cubensis Fungi
Foster, K., Morrison, I., Daniel, S., Antoine, J. M. R., Thankappan, B. M., Haye, W. D. L., Tyler, M. W., Grant, C. N., & Delgoda, R. (2025) · Journal of AOAC International · doi:10.1093/jaoacint/qsaf072 · Cited by 6
Bruno, V., López-Canul, M., Richardson, B., Camarini, R., Marcourakis, T., & Gobbi, G. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251368361 · Cited by 8
“…and Drug Administration table of conversion (Nair and Jacob, 2016) and considering that rodents have less affinity than human for the 5-HT 2A receptors (Tan et al., 1999), the 10 mg/kg corresponds approximately to the dose used in human studies (Carhart-Harris et al., 2021; Goodwin et al., 2022).”
Gold, N. D., Mallard, A. J., Hermann, J. C., Zeifman, R. J., Pagni, B. A., Bogenschutz, M. P., & Ross, S. (2023) · Journal of Palliative Medicine · doi:10.1089/jpm.2022.0604 · Cited by 6
“27,32,36,39 It is generally thought that the psychotherapeutic effects are mediated by both the participant-specific content of a high-dose psychedelic experience, and the psychedelic-induced critical period of neuroplasticity where individuals are particularly open to making changes to behaviors…”
Abrams, S. K., Rabinovitch, B. S., Zafar, R. R., Aziz, A. S., Cherup, N. P., McMillan, D. W., Nielson, J. L., & Lewis, E. C. (2023) · Neurotrauma Reports · doi:10.1089/neur.2023.0022 · Cited by 7
“To date, PAT has avoided or actively excluded persons with chronic or serious ‘‘medically significant’’ cardiovascular and autonomic status as well as those with specific neurological diagnoses.(10,11) This has included persons with spinal cord injury (SCI), who have a high prevalence of treatment-resistant mental hea…”
BackgroundDevelopment of the Japanese version of the 30‐item Mystical Experience Questionnaire
Yonezawa, K., Tani, H., Nakajima, S., & Uchida, H. (2023) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12377 · Cited by 6
The Key Role of Intracellular 5-HT2A Receptors: A Turning Point in Psychedelic Research?
Sapienza, J. (2023) · Psychoactives · doi:10.3390/psychoactives2040018 · Cited by 7
Reichelt, A. C., Vermetten, E. H. G. J. M., & Dunkley, B. T. (2023) · Journal of Military Veteran and Family Health · doi:10.3138/jmvfh-2022-0084 · Cited by 6
Adam, A. S., LaMalfa, K. S., Razavi, Y., Kohut, S. J., & Kangas, B. D. (2024) · Psychedelic Medicine · doi:10.1089/psymed.2023.0049 · Cited by 6
“10 Another timely example is the 5-HT2A agonist psilocy-bin, a psychedelic shown to significantly improve depression and anxiety in treatment-resistant patients, 11–13 with efficacy that has recently been validated in Phase 2 clinical trials.”
Pasculli, G., Busan, P., Jackson, E. S., Alm, P. A., Gregorio, D. D., Maguire, G. A., Goodwin, G. M., Gobbi, G., Erritzøe, D., & Carhart-Harris, R. L. (2024) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2024.1402549 · Cited by 7
Self-citationJones, G. M., Ricard, J. A., & Nock, M. K. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1169686 · Cited by 8
Zhao, R., Luo, J., Chung, S. K., & Xu, B. (2024) · Food Science & Nutrition · doi:10.1002/fsn3.4446 · Cited by 6
Majić, T., Schmidt, T. T., Gröticke, A., Gasser, P., Richards, W. A., Riemer, T., & Evens, R. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251326937 · Cited by 7
“…psychedelics have been proposed for treating certain mental health conditions (Reiff et al., 2020), such as treatment-resistant depression (Carhart-Harris et al., 2021; Goodwin et al., 2022), substance-use disorders (Bogenschutz et al., 2022), and depression and anxiety in patients with…”
Perspectives on the success rate of current antidepressant pharmacotherapy
Goldberg, J. F. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2138333 · Cited by 8
“receptor antagonists beyond ketamine, such as esmethadone [96] and dextromethorphan-bupropion [97]; neurosteroids such as zuranolone [98]; and psychedelics that are believed to enhance neuroplasticity such as psilocybin [99].”
BackgroundHovmand, O. R., Jensen, M. E., Juul, T. S., Madsen, M. K., Fisher, P. M., & Stenbæk, D. S. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2302186 · Cited by 7
Future directions for clinical psilocybin research: The relaxed symptom network.
Lewis-Healey, E., Laukkonen, R., & van Elk, M. (2022) · Psychology & Neuroscience · doi:10.1037/pne0000290 · Cited by 7
“…for example through a mobile application, researchers may have been able to gain a deeper insight into the specific fluctuations of symptomatology, and more through digital means has recently been highlighted as a tool that may push psychedelic research forward (Carhart-Harris et al., 2021b).”
BackgroundPsychedelics for Psychiatric Disorders: Promise, Not Panacea
Earleywine, M., & Herrmann, Z. M. (2022) · Psychiatric Annals · doi:10.3928/00485713-20220810-01 · Cited by 7
Myers, M. G., & Toal, C. B. (1995) · PubMed · Cited by 7
What are set and setting: Reducing vagueness to improve research and clinical practice
Patch, K., & Smith, W. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251337372 · Cited by 8
“These compounds show promise in treating major depression, substance use disorders, and psychological suffering in terminally ill patients (Carhart-Harris et al., 2021; Goodwin et al., 2022; Griffiths et al., 2016).”
Psilocybin’s acute and persistent brain effects: a precision imaging drug trial
Subramanian, S., Reneau, T. R., Perry, D., Chacko, R. V., Laumann, T. O., Flavin, K., Horan, C., Schweiger, J. A., Metcalf, N. V., Lenze, E. J., et al. (2025) · Scientific Data · doi:10.1038/s41597-025-05189-0 · Cited by 7
“…(PSIL) is a serotonin receptor 2 A (5-HT2A) agonist that has shown positive, rapid benefits in clinical trials for numerous psychiatric indications, including depression 1–4 , end-of-life anxiety 5,6 , obsessive compulsive disorder 7 , eating disorders 8,9 , and alcohol use disorder 10–12 .”
Jiwani, Z., Goldberg, S. B., Stroud, J., Young, J., Curtin, J., Dunne, J. D., Simonsson, O., Webb, C. A., Carhart-Harris, R., & Schlosser, M. (2024) · doi:10.1101/2024.08.27.24312677 · Cited by 6
Self-citationIn naturalistic psychedelic use, group use is common and acceptable
Byrne, K., Lindsay, S., Baker, N. J., Schmutz, C., & Lewis, B. (2023) · Journal of Psychedelic Studies · doi:10.1556/2054.2023.00261 · Cited by 6
Better Biomarkers, Faster Drugs, Stronger Models: Progress Towards Precision Psychiatry.
Siegel, J. S., Pearson, C. S., & Lenze, E. J. (2023) · PubMed Central · Cited by 7
Downey, A. E., Bradley, E., Lerche, A. S., O’Donovan, A., Krystal, A. D., & Woolley, J. D. (2024) · Psychedelic Medicine · doi:10.1089/psymed.2023.0051 · Cited by 6
“3,5 Again, rates of relevant family histories were not reported so the lack of serious adverse events does not necessarily clarify the safety of dosing people with a family history of BD.”
Psychedelics for treating psychiatric disorders: from circuit mechanisms to applications
Li, J., Jiang, Y., Cheng, D., Cheng, J., Ji, H., Wang, X., & Yuan, T. (2024) · 中国科学通报:英文版 · doi:10.1016/j.scib.2024.11.033 · Cited by 5
Pathway engineering for the biosynthesis of psychedelics
Abrahms, Z. N., Sen, A. K., & Jones, J. A. (2025) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2025.103314 · Cited by 5
Mueller, L., Klaiber, A., Ley, L., Becker, A., Thomann, J., Luethi, D., Schmid, Y., & Liechti, M. E. (2025) · Clinical Pharmacokinetics · doi:10.1007/s40262-025-01544-x · Cited by 8
The emotional architecture of the psychedelic brain
Moujaes, F., Rieser, N. M., Belinger, L., Herdener, M., Zahid, Z., & Preller, K. H. (2025) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2025.07.006 · Cited by 6
Microdosing Psychedelics to Restore Synaptic Density in Schizophrenia
Sapienza, J., Spangaro, M., Comai, S., Sabé, M., Torre, J. T. L., Buonarroti, M., Cavallaro, R., & Bosia, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26188949 · Cited by 7
“Indeed, antidepressant properties of psilocybin are widely reported by several randomized clinical trials (RCTs) [63–65].”
Marinis, J., Clarke, S. T., Guerin, A. A., Guastella, A. J., & Bedi, G. (2025) · BJPsych Open · doi:10.1192/bjo.2025.10847 · Cited by 6
Martens, M., Cunha, B. G., Erritzoe, D., Nutt, D., Carhart-Harris, R., & Harmer, C. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03693-w · Cited by 3
Self-citationHorato, N., Dalvi-Garcia, F., Dutra, P. E. P., & Nardi, A. E. (2026) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002122 · Cited by 5
Syed, O. A., Tsang, B., Nestor, S. M., Lipsman, N., Husain, M. I., Alam, F., & Giacobbe, P. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106573 · Cited by 6
Serotonergic modulation of excitatory synapse development and plasticity
Chang, V. N., Ogelman, R., Vargas, R. S., & Oh, W. C. (2026) · Molecules and Cells · doi:10.1016/j.mocell.2026.100346 · Cited by 5
How to set up a psychedelic study: Unique considerations for research involving human participants
Glennon, M. J., Bird, C., Yadav, P., Kleine, P., Suseelan, S., Boman-Markaki, C., Kotoula, V., Butler, M., Leech, R., Roseman, L., et al. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106657 · Cited by 5
The Therapeutic Potential of Psilocybin in Alcohol Use Disorder Recovery: A Literature Review
Venugopal, K., & Bedri, N. (2023) · Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal · doi:10.26685/urncst.420 · Cited by 7
Bormann, N. L., Weber, A. N., Miskle, B., Woodson-DeFauw, N., Arndt, S. V., & Lynch, A. C. (2023) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-023-02448-6 · Cited by 8
Davis, A. K., Timmermann, C., Bernal, A. M. O., Lancelotta, R., Nayak, S. M., Sepeda, N. D., Nikolaidis, A., & Griffiths, R. R. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2232379 · Cited by 7
“…(LSD), or ayahuasca in carefully monitored settings have shown preliminary safety and efficacy for such indications as Major Depressive Disorder (Carhart-Harris et al. 2021; Davis et al. 2021; Palhano-Fontes et al. 2019), nicotine use disorder (Johnson et al. 2014), and alcohol use disorder…”
Ethische Aspekte der Therapie mit Psychedelika
Repantis, D., Koslowski, M., & Fink, S. B. (2024) · Die Psychotherapie · doi:10.1007/s00278-024-00710-z · Cited by 5
Jiang, Y., Cheng, Y., Du, Z., Shen, Y., Zhou, Q., Ji, Y., & Zhu, H. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241249651 · Cited by 5
“…single S-enantiomer derivative of citalopram, escitalo-pram oxalate has demonstrated high selective reuptake inhibition of serotonin (serotonin) in both in vitro and in vivo experiments, with relatively minor effects on norepinephrine and dopamine (Carhart-Harris et al., 2021; Hoge et al., 2023).”
Background
Metadata
- Authors
- Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J.
- Affiliations
- Imperial College London (GB)
- From the Centre for Psychedelic Research, Department of Brain Sciences, Faculty of Medicine, Imperial College London, London.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-04-15
- Volume
- 384
- Issue
- 15
- Pages
- 1402-1411
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3156937150
- Cited by
- 1,391
- References
- 26
- Citations by year
- 2026: 200 · 2025: 278 · 2024: 287 · 2023: 284 · 2022: 247 · 2021: 92
- FWCI
- 154.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Alex Mosley Charitable Trust (NA)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- psilocybin, escitalopram, major depressive disorder, antidepressant efficacy, psychedelic therapy, selective serotonin reuptake inhibitors, depression remission, treatment-resistant depression, psychological support, hallucinations, dissociation, synesthesia, anxiety disorders
- MeSH terms
- Adult, Antidepressive Agents, Major Depressive Disorder, Double-Blind Method, Female, Hallucinogens, Humans, Male, Middle Aged, Psilocybin, Surveys and Questionnaires, Citalopram, Antidepressive Agents, Second-Generation, Young Adult, Self Report
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.